171047-47-5|Ladirubicin|(2S,3S,4S,6R)-6-(((1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl)oxy)-4-(aziridin-1-yl)-2-methyltetrahydro-2H-pyran-3-yl methanesulfonate|-范德生物科技公司

Ladirubicin

NMR下载 COA and HPLC MSDS下载
names：
(2S,3S,4S,6R)-6-(((1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl)oxy)-4-(aziridin-1-yl)-2-methyltetrahydro-2H-pyran-3-yl methanesulfonate
CAS号：
171047-47-5
MDL Number：
MF(分子式)： C29H31NO11S MW(分子量)： 601.62
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Ladirubicin
英文别名	Ladirubicin;
CAS号	171047-47-5
SMILES	C[C@H]1[C@@H](OS(=O)(C)=O)[C@@H](N2CC2)C[C@H](O[C@H]3C[C@@](C(C)=O)(O)Cc4c(O)c(C(c5c(C6=O)cccc5)=O)c6c(O)c43)O1
Inchi	InChI=1S/C29H31NO11S/c1-13-28(41-42(3,37)38)18(30-8-9-30)10-20(39-13)40-19-12-29(36,14(2)31)11-17-21(19)27(35)23-22(26(17)34)24(32)15-6-4-5-7-16(15)25(23)33/h4-7,13,18-20,28,34-36H,8-12H2,1-3H3/t13-,18-,19-,20-,28+,29-/m0/s1
InchiKey	VMDWTZZCNDEKIO-CBNJBKGYSA-N
分子式 Formula	C29H31NO11S
分子量 Molecular Weight	601.62
闪点 FP
熔点 Melting point
沸点 Boiling point
Polarizability极化度
密度 Density
蒸汽压 Vapor Pressure
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Ladirubicin(CAS:171047-47-5):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Ladirubicin is an anthracyclines analogue, and the leading compound of alkylcyclines.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Soares PI, Dias SJ, Novo CM, Ferreira IM, Borges JP. Doxorubicin vs. ladirubicin: methods for improving osteosarcoma treatment. Mini Rev Med Chem. 2012 Oct;12(12):1239-49. PubMed PMID: 22512558.

[2]Pasello M, Hattinger CM, Stoico G, Manara MC, Benini S, Geroni C, Mercuri M, Scotlandi K, Picci P, Serra M. 4-Demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548): a promising new candidate for chemotherapeutic treatment of osteosarcoma patients. Eur J Cancer. 2005 Sep;41(14):2184-95. PubMed PMID: 16140527.

[3] Moneta D, Geroni C, Valota O, Grossi P, de Jonge MJ, Brughera M, Colajori E, Ghielmini M, Sessa C. Predicting the maximum-tolerated dose of PNU-159548 (4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin) in humans using CFU-GM clonogenic assays and prospective validation. Eur J Cancer. 2003 Mar;39(5):675-83. PubMed PMID: 12628848.

[4] Marchini S, Damia G, Broggini M, Pennella G, Ripamonti M, Marsiglio A, Geroni C. 4-Demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548), a novel anticancer agent active against tumor cell lines with different resistance mechanisms. Cancer Res. 2001 Mar 1;61(5):1991-5. PubMed PMID: 11280757.

[5] Geroni C, Ripamonti M, Arrigoni C, Fiorentini F, Capolongo L, Moneta D, Marchini S, Della Torre P, Albanese C, Lamparelli MG, Ciomei M, Rossi R, Caruso M. Pharmacological and toxicological aspects of 4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548): a novel antineoplastic agent. Cancer Res. 2001 Mar 1;61(5):1983-90. PubMed PMID: 11280756.

6: Della Torre P, Podestà A, Imondi AR, Moneta D, Sammartini U, Arrigoni C, Terron A, Brughera M. PNU-159548, a novel cytotoxic antitumor agent with a low cardiotoxic potential. Cancer Chemother Pharmacol. 2001 Apr;47(4):355-60. PubMed PMID: 11345653.7: Breda M, Basileo G, Fonte G, Long J, James CA. Determination of 4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyldaunorubicin+ ++ and its 13-hydroxy metabolite by direct injection of human plasma into a column-switching liquid chromatography system with mass spectrometric detection. J Chromatogr A. 1999 Aug 27;854(1-2):81-92. PubMed PMID: 10497930.8: de Jonge MJ, Verweij J, van der Gaast A, Valota O, Mora O, Planting AS, Mantel MA, Bosch SV, Lechuga MJ, Fiorentini F, Hess D, Sessa C. Phase I and pharmacokinetic studies of PNU-159548, a novel alkycycline, administered intravenously to patients with advanced solid tumours. Eur J Cancer. 2002 Dec;38(18):2407-15. PubMed PMID: 12460785.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开